Ipsen Pharma Biotech SAS

The purpose of this study is to further characterize the clinical efficacy and safety of Lanreotide Autogel as a monotherapy for tumor control in Chinese participants in routine clinical practice to supplement the bridging study and support the clinical trial application. The medical records were reviewed approximately 48 weeks after the start of treatment with Lanreotide Autogel.

The purpose of this study was to observe whether the efficacy of triptorelin 3-month extended-release in Chinese children with central precocious puberty (CPP) has the same or similar trend as that in overseas CPP populations. The main purpose was to evaluate the proportion of Chinese children with CPP whose luteinizing hormone (LH) levels were suppressed to prepubertal levels (defined as LH peak ≤3 IU/L after intravenous (i.v.) GnRH stimulation) in the third month when triptorelin 3-month extended-release was used to treat CPP.

To evaluate the efficacy, safety profile, and pharmacokinetics of 3-month extended-release triptorelin pamoate in the treatment of Chinese women with endometriosis and compare it with 1-month extended-release triptorelin acetate. To evaluate efficacy parameters after week 12 and explore the PK/pharmacodynamics of 3-month extended-release triptorelin pamoate in subgroups of subjects.